These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7694894)

  • 21. Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C.
    Tanno H; Fernández JL; Rendo P; del Pino N; Viola L; Terg R; Pérez V
    J Viral Hepat; 1995; 2(2):97-102. PubMed ID: 7493304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C.
    Brillanti S; Masci C; Ricci P; Miglioli M; Barbara L
    Hepatology; 1992 Jun; 15(6):998-1001. PubMed ID: 1317344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.
    Marcellin P; Pouteau M; Martinot-Peignoux M; Degos F; Duchatelle V; Boyer N; Lemonnier C; Degott C; Erlinger S; Benhamou JP
    Gastroenterology; 1995 Jul; 109(1):156-65. PubMed ID: 7540996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation.
    Wright TL; Combs C; Kim M; Ferrell L; Bacchetti P; Ascher N; Roberts J; Wilber J; Sheridan P; Urdea M
    Hepatology; 1994 Oct; 20(4 Pt 1):773-9. PubMed ID: 7927216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment.
    Magrin S; Craxi A; Fabiano C; Simonetti RG; Fiorentino G; Marino L; Diquattro O; Di Marco V; Loiacono O; Volpes R
    Hepatology; 1994 Feb; 19(2):273-9. PubMed ID: 8294085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of hepatitis C viremia in patients receiving hemodialysis.
    Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
    Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy.
    Boran M; Cetin S
    Nephron; 1999; 82(1):22-6. PubMed ID: 10224480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus RNA and anti-N14 antibody levels during interferon alpha therapy for chronic hepatitis C.
    Oketani M; Tanaka K; Sho Y; Maeda E; Miyazaki H; Arima T
    Intern Med; 1994 Oct; 33(10):588-92. PubMed ID: 7530068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant interferon-alfa therapy in children with chronic hepatitis C.
    Bortolotti F; Giacchino R; Vajro P; Barbera C; Crivellaro C; Alberti A; Nebbia G; Zancan L; De Moliner L; Bertolini A
    Hepatology; 1995 Dec; 22(6):1623-7. PubMed ID: 7489965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study.
    Brillanti S; Garson JA; Tuke PW; Ring C; Briggs M; Masci C; Miglioli M; Barbara L; Tedder RS
    J Med Virol; 1991 Jun; 34(2):136-41. PubMed ID: 1716296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-up.
    Diodati G; Bonetti P; Tagger A; Casarin C; Noventa F; Ribero M; Fasola M; Ruol A; Realdi G
    Dig Dis Sci; 1994 Nov; 39(11):2497-502. PubMed ID: 7525169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome.
    Quiroga JA; van Binsbergen J; Wang CY; Pardo M; Navas S; Trines C; Herrero M; Carreño V
    Hepatology; 1995 Dec; 22(6):1635-40. PubMed ID: 7489967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon.
    Shindo M; Di Bisceglie AM; Hoofnagle JH
    Hepatology; 1992 Jun; 15(6):1013-6. PubMed ID: 1317338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.
    Reichard O; Glaumann H; Norkrans G; Wejstål R; Fryden A; Schvarcz R; Weiland O
    Liver; 1994 Aug; 14(4):169-74. PubMed ID: 7526108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients.
    Raptopoulou-Gigi M; Spaia S; Garifallos A; Xenou P; Orphanou H; Zarafidou E; Petridou P; Vrettou H; Vagionas G; Galaktidou G
    Nephrol Dial Transplant; 1995 Oct; 10(10):1834-7. PubMed ID: 8592590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.